Market Newsdesk

SAN FRANCISCO, Dec. 14, 2020 (GLOBE NEWSWIRE) — Researchers at Yale published positive results from a pilot study of a novel combination therapy in patients with Mild Cognitive Impairment related to Alcohol Use. The therapy used the drug Donepezil in combination with the brain training BrainHQ from Posit Science.

In their report in the journal Substance Abuse, the researchers note that Alcohol Use Disorders (AUDs) significantly impact public health, cost billions of dollars annually, and are prevalent in Veterans. The Veterans in this study also were diagnosed with Mild Cognitive Impairment (MCI), a pre-dementia condition. AUD contributes to Alzheimer’s risk, and MCI worsens the cognitive abilities for self-regulation — setting the stage for a downward spiral. AUD-related MCI (AUD-MCI) is a medical classification for which there is no evidence-based treatment.

BrainHQ has been used as an intervention in 16prior studies of MCI and has shown a variety of benefits, including better: cognition (speed, attention, memory, global cognition); neurological health (connectivity in networks governing behavior, thought, and adaptation to stress); physical health (heart rate variability); and day-to-day abilities (instrumental activities of daily living, depressive symptoms).

BrainHQ also has been used in a study of Substance Use Disorder (SUD) by this same team of Yale researchers, who noted that BrainHQ plus traditional work therapy resulted in improved neurocognitive performance and high rates of recovery from SUD.

Donepezil (often under the brand Aricept) is frequently used to treat Alzheimer’s disease (although it is not approved for MCI). Recent pre-clinical research also suggests it might be effective in the treatment of AUD.

This is the first study that has combined BrainHQ with Donepezil.

This pilot involved 11 participants in a 21-day substance abuse day program of the Veterans Administration. Participants were male Veterans with AUD-MCI, 71.5% White, average age of 58.9 years, and an average 42.1-year history of heavy drinking. For 13 weeks, they were administered Donepezil daily and asked to complete a BrainHQ session (of up to an hour), five days per week. Adherence to the protocol was strong, with an average total of 48.4 hours of BrainHQ training.

The researchers reported significant overall cognitive improvements — both within the group (comparing before and after) and when compared to a matched control from a prior study. The improvements were strongest in measures of memory and executive function. The researchers also saw a strong trend in clinical results, with 90.9% of participants showing good clinical recovery on a Clinical Global Impression scale, compared with 59.5% of controls.

“This study nicely brings together two distinct areas of research on BrainHQ — in MCI and SUDs,” said Dr. Henry Mahncke, Posit Science CEO, “and also suggests there may be combination drug therapies that could address some difficult-to-treat conditions. We plan to explore further research and clinical opportunities.”

BrainHQ exercises have shown benefits in 100+ studies, and are offered by leading health plans, medical centers, clinics, libraries, and communities. Consumers can try BrainHQ for free at http://www.brainhq.com.

Contact: [email protected]

Click


here


to join the case

LOS ANGELES, Dec. 14, 2020 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Semiconductor Manufacturing International Corporation (“Semiconductor” or “the Company”) (NYSE: GWRE) investors that acquired securities between April 23, 2020 and September 26, 2020.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

It is alleged in the complaint that Semiconductor made misleading and/or false statements to the market. SMIC suffered from an increased chance of U.S. sanctions as a result of an “unacceptable risk” that equipment supplied to Semiconductor would be used for military applications. Semiconductor’s suppliers would require “difficult-to-obtain” individual export licenses due to these restrictions. Semiconductor’s public statements were false and materially misleading, based on these facts. Investors suffered damages when the market learned the truth about SMIC.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

Service Availability is Expected in January 2021

MOUNTAIN VIEW, CA and REHOVOT, ISRAEL, Dec. 14, 2020 (GLOBE NEWSWIRE) — via NewMediaWire – Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, and Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced the signing of a distribution agreement for AditxtScore™ for COVID-19, with planned availability in January 2021. 

Todos Medical has secured the rights to distribute AditxtScore™ for COVID-19 to monitor immunity against SARS-CoV-2. Blood samples will be collected by Todos and/or its network of partners and sent to Aditxt’s CLIA accredited AditxtScore™ Center for processing. 

Amro Albanna, Co-founder and CEO of Aditxt, commented, “This agreement marks a milestone for AditxtScore™ and Aditxt as a whole. Todos Medical is Aditxt’s first commercial customer for our proprietary AditxtScore™ immune monitoring platform and its first application, AditxtScore™ for COVID-19. As the availability of COVID-19 vaccines increases, the need to understand an individual’s immune profile to measure its effectiveness, increases as well. We look forward to working with the team at Todos and providing our innovative AditxtScore™ platform as a complement to the suite of testing solutions that they offer.”

Gerald Commissiong, President and CEO of Todos Medical, added, “After a thorough review of the immune-related COVID-19 testing market, we believe that Aditxt’s platform technology represents a unique multidimensional view of the immune system that will be critical to allow physicians and scientists to categorize immune responses to vaccines and therapeutic approaches for COVID-19 in order to determine which interventions to use for which patients in a personalized way. As vaccines for COVID-19 are rolled out, it is imperative that we evaluate patients’ immune status prior to and after vaccination, and track when immunity is gained and how long it might last with repeat immune testing. The AditxtScore™ for COVID-19 scoring system will initially include antibody and neutralizing antibodies, and will soon include T-cell and B-cell responses as well, which makes it the most comprehensive immune profiling tool for COVID-19 available in the market.”

About Aditx Therapeutics

Aditxt is developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring biotechnology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming biotechnology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com and www.aditxtscore.com

About Todos Medical Ltd.

Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. For more information, please visit https://www.todosmedical.com/.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled “Risk Factors” in the Company’s prospectus, dated September 1, 2020, that was filed with the Securities and Exchange Commission under File No. 333-248491, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Aditxt Investor Relations:

PCG Advisory
Jeff Ramson
Chief Executive Officer
646-863-6341
[email protected]

Todos Investor Relations:

Kim Sutton Golodetz
LHA Investor Relations
Senior Vice President
(212) 838-3777
[email protected]

Todos Corporate Contact:

Priyanka Misra
Todos Medical
(917) 983-4229 ext. 103
[email protected]

CARLISLE, Pa., Dec. 14, 2020 (GLOBE NEWSWIRE) — The GIANT Company announced today that it will donate more than 3,000 hams to 14 partner food banks across Pennsylvania, Maryland, Virginia, and West Virginia this holiday season. An annual tradition for the company, the ham donations bring its brand platform For Today’s Table™ to life, ensuring families can celebrate the season with a staple in their holiday meals.

“With more and more people turning to their local food bank or pantry for assistance than ever before, our hunger relief partners are telling us they expect an incredible demand for food throughout the holiday season,” said Emily Steinkamp, manager of social impact, The GIANT Company. “The GIANT Company believes every family should be able to enjoy a meal together and donating hams is one way we are able to help make that possible. It’s our hope this donation makes the holidays just a bit brighter for our neighbors in need.”

Hams
will be donated t
his week t
o the following food distribution organizations:

• Blue Ridge Area Food Bank in Staunton, Va.
• Caring for Friends in Philadelphia, Pa.
• Central Pennsylvania Food Bank in Harrisburg, Pa.
• Chester County Food Bank in Exton, Pa.
• CityTeam Chester in Chester, Pa.
• The Columbia Food Bank in Columbia, Pa.
• Dubois Area Food Pantry in DuBois, Pa.
• Helping Harvest Fresh Food Bank in Reading, Pa.
• Jefferson County Community Ministries in Charles Town, WV.
• Maryland Food Bank in Hagerstown, Md.
• New Britain Baptist Food Larder in New Britain, Pa.
• New Hope Ministries in Mechanicsburg, Pa.
• Philabundance in Philadelphia, Pa.
• Second Harvest Food Bank in Nazareth, Pa.

“As we gather together this holiday season, we give thanks for what we have and pray for a day one day soon when we will be able to join with all those we love. We especially remember those who have been impacted by the pandemic through illness, job loss, and those who experience hunger,” said Eric Saunders, executive director, New Hope Ministries. “New Hope Ministries helps our neighbors by providing those in need and could not do this without the support of our corporate partners like The GIANT Company. We are truly grateful for their generosity.”  

About
The
GIANT Company

The GIANT Company​
 
believes that no matter where or how, when meals happen, families connect, and when families connect meaningfully, good happens. Guided by its brand platform, For Today’s Table™, the omni-channel retailer proudly serves millions of neighbors across Pennsylvania, Maryland, Virginia and West Virginia. A Great Place to Work™ certified company with more than 35,000 talented team members supporting nearly 190 stores, 132 pharmacies, 105 fuel stations, and over 145 online pickup hubs and grocery delivery service in hundreds of zip codes, The GIANT Company is changing the customer experience and connecting families for a better future. Founded in 1923 in Carlisle, Pa., The GIANT Company family of brands includes GIANT, MARTIN’S, GIANT Heirloom Market, GIANT Direct and MARTIN’S Direct. The GIANT Company is a company of Ahold Delhaize USA. For more information, visit the
 

GIANT

 
or
 

MARTIN’S

websites.

Contact:

Ashley Flower
860-966-1727
[email protected]

Brink POS Integrates with Mobivity’s Recurrency to Deliver Actionable Insights
and Power 1:1 Digital Engagement

PHOENIX, Dec. 14, 2020 (GLOBE NEWSWIRE) — Mobivity Holdings Corp. (OTCQB: MFON) a global provider of personalized customer engagement solutions that drive customer frequency and spend, announced its partnership with ParTech, Inc., a leading global provider of point of sale (POS) software and integrated technical solutions to the restaurant and retail industries. ParTech, Inc. is a wholly owned subsidiary of PAR Technology Corporation (NYSE: PAR). Mobivity is integrating its Recurrency™ platform with PAR Technology’s Brink POS® delivering actionable insights from POS data -accelerating brands’ digital transformation with:

• Increased guest frequency and spend through personalized, multichannel, digital offers and promotions;
• Machine learning techniques to predict and measure offer and product performance;
• AI features to activate in-store and online transaction data for rapid analytics and insights to fuel intelligent personalization and promotions;
• 1:1 guest engagement through channels such as mobile messaging and dynamic takeout and delivery receipts; and
• Omnichannel digital loyalty programs. 

“PAR is pleased to welcome Mobivity into our Brink POS integration ecosystem,” said Stephen Lee, Director of Strategic Partnerships at ParTech, Inc. “The combination of Mobivity’s Recurrency platform and our Brink POS will allow restaurants to quickly understand and adapt to guest behavior using intelligent data and create personalized and branded experiences that ultimately increase guest engagement.”

Customers of Brink POS can now utilize Mobivity’s Recurrency AI/machine learning to analyze the various data from their POS. By accurately attributing promotions to transactions and being able to identify pre- and post-redemption purchase activity, Mobivity helps restauranteurs and franchisees determine the most effective marketing approach based on guest frequency and spend. Recurrency uses these insights to provide restaurants personalized and intelligent offers, audience segmentation, offer and promotion management and codes. These codes can be delivered to consumers via Mobivity’s Unified Mobile Messaging or through other owned or paid media channel brands in which they engage.

“Integrating Mobivity into Brink POS ecosystem helps PAR reinforce its mission by enabling restaurants to provide guests a more engaged experience. This starts by making sense of the POS data,” said Dennis Becker, Mobivity Chairman and CEO. “This last year has been a challenge for restaurants and Mobivity is playing a significant role with best-of-breed partners such as ParTech to keep these vital businesses open. The impact we are making on businesses is significant to brands’ digital transformation today and tomorrow.”

To learn more about how Mobivity works with the Brink POS system, schedule a demo with the Mobivity team.

About PAR Technology Corporation 

PAR Technology Corporation through its wholly owned subsidiary ParTech, Inc., is a customer success-driven, global restaurant and retail technology company with over 100,000 restaurants in more than 110 countries using its point of sale hardware and software. ParTech’s Brink POS integration ecosystem enables quick service, fast casual, table service, and cloud restaurants to improve their operational efficiency by combining its cloud-based POS software with the world’s leading restaurant technology platforms. PAR Technology Corporation’s stock is traded on the New York Stock Exchange under the symbol PAR. For more information, visit www.partech.com or connect with PAR on Facebook or Twitter.

About Mobivity

Brick and mortar stores struggle to manage customer connections in a digital world. Mobivity provides a platform to connect national restaurants, retailers, personal care brands, and their partners with customers to increase retention, visits, and spend. Mobivity’s Recurrency platform increases customer engagement and frequency by capturing detailed POS transaction data, analyzing customer habits, and motivating customers and employees through data-driven messaging applications and rewards. For more information about Mobivity, visit mobivity.com or call (877) 282-7660.

Forward Looking Statement

This press release contains forward-looking statements concerning Mobivity Holdings Corp. within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those forward-looking statements include statements regarding the expansion of the Company’s addressable markets and the Company’s expectations for the timing and growth of the Company’s revenue from a new customer. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, our ability to successfully market and sell our products and services to the convenience store industry; deploy our product and services to a new customer; changes in the laws and regulations affecting the mobile marketing industry and those other risks set forth in Mobivity Holdings Corp.’s annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 30, 2020 and subsequently filed quarterly reports on Form 10-Q. Mobivity Holdings Corp. cautions readers not to place undue reliance on any forward-looking statements. Mobivity Holdings Corp. does not undertake, and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Media Contact:

Jennifer Handshew • Marketing Communications, Mobivity
[email protected] • (917) 359-8838

Investor Relations Contacts

Lisa Brennan • Chief Financial Officer, Mobivity
(877) 282-7660

Brett Maas • Managing Partner, Hayden IR
[email protected] • (646) 536-7331

 

THE WOODLANDS, Texas, Dec. 14, 2020 (GLOBE NEWSWIRE) — ChampionX Corporation (NYSE: CHX) (the “Company” or “ChampionX”) announced that, pursuant to the Company’s previously announced cash tender offer (the “Tender Offer”) with respect to the securities described in the table below (the “Notes”), the principal amount of Notes that were validly tendered and not validly withdrawn on or before 5:00 p.m., New York City time, on December 11, 2020 (the “Early Tender Date”), according to information provided by D.F. King & Co., Inc., the tender agent for the Tender Offer, and the principal amount of Notes to be accepted for purchase by the Company in accordance with the terms of the Tender Offer, are as set forth in the table below. Because the withdrawal deadline relating to the Tender Offer expired at 5:00 p.m., New York City time, on December 11, 2020, these Notes, as well as any subsequently tendered Notes, may not be withdrawn.

The terms and conditions of the Tender Offer are described in detail in the Offer to Purchase, dated as of November 30, 2020 (the “Offer to Purchase”). Holders are encouraged to read the Offer to Purchase carefully.

Title of Security

CUSIP Number

Principal Amount Outstanding

Tender Cap

Principal Amount Tendered

Percentage of Outstanding Amount Tendered

Principal Amount to be Accepted for Purchase

6.375% Senior Notes due 2026

03755LAC8

$300,000,000

$100,000,000

$22,953,000

7.65%

$22,953,000

In addition, the Company announced today that it has amended the terms and conditions of the Tender Offer to extend the deadline for receiving the early tender premium of $30.00 for each $1,000 principal amount of Notes tendered to be through 11:59 p.m., New York City time, on December 28, 2020, unless extended by the Company (such time and date, as the same may be extended, the “Expiration Date”). Subject to this amendment, all other terms and conditions of the Tenders Offer remain unchanged and are being made solely pursuant to the terms and conditions set forth in the Offer to Purchase.

Holders of Notes who validly tendered (and did not validly withdraw) their Notes on or before the Early Tender Date are eligible to receive, for each $1,000 principal amount of the Notes, $1,010.00, which includes an early tender premium of $30 per $1,000 principal amount of Notes tendered by such holders that were accepted for purchase. Holders whose Notes were accepted for purchase pursuant to the Tender Offer will also receive accrued and unpaid interest on the purchased Notes from the last interest payment date for the Notes up to, but not including, the settlement date for the Notes. Payment for Notes tendered prior to the Early Tender Date and accepted for purchase pursuant to the Tender Offer will be made on the early settlement date, which is expected to be December 15, 2020.

Acceptance of Notes for purchase in the Tender Offer is subject to the Tender Cap and proration, all as described in the Offer to Purchase. All Notes that were tendered for purchase prior to the Early Tender Date (and not validly withdrawn at or prior to the Early Tender Date) will have priority over any Notes that are tendered for purchase after the Early Tender Date. Notes not accepted for purchase, including Notes not accepted because of proration, will be returned promptly.

J.P. Morgan Securities LLC is acting as dealer manager for the Tender Offer. Questions regarding the Tender Offers may be directed to J.P. Morgan Securities LLC toll-free at (866) 834-4666 or collect at (212) 834-4087.

D.F. King & Co., Inc. is acting as tender and information agent for the Tender Offer. Requests for copies of the Offer to Purchase may be directed to D.F. King & Co., Inc. at (212) 269-5550 (banks and brokers), (800) 591-6313 (toll-free) or email at [email protected].

This press release is for informational purposes only and does not constitute an offer to purchase or the solicitation of an offer to sell any Notes. The Tender Offer is not being made in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. No recommendation is made as to whether or not holders of any Notes should tender their Notes pursuant to the Tender Offer. The Tender Offer is being made solely pursuant to the Offer to Purchase, which more fully sets forth and governs the terms and conditions of the Tender Offer. The Offer to Purchase contains important information and should be read carefully before any decision is made with respect to the Tender Offer.

About ChampionX

ChampionX (formerly known as Apergy Corporation) is a global leader in chemistry solutions and highly engineered equipment and technologies that help companies drill for and produce oil and gas safely and efficiently around the world. ChampionX’s products provide efficient functioning throughout the lifecycle of a well with a focus on the production phase of wells.

Forward-Looking Statements

This news release contains statements relating to future actions and results, which are “forward-looking statements” within the meaning of the Securities Exchange Act of 1934, as amended. and the Private Securities Litigation Reform Act of 1995. Such statements relate to, among other things, ChampionX’s market position and growth opportunities. Forward-looking statements include, statements related to ChampionX’s expectations regarding the performance of the business, financial results, liquidity and capital resources of ChampionX. Forward-looking statements are subject to inherent risks and uncertainties that could cause actual results to differ materially from current expectations, including, but not limited to, (1) demand for ChampionX’s products and services, which is affected by the price and demand for crude oil and natural gas, (2) ChampionX’s ability to successfully compete in its industry, (3) ChampionX’s ability to develop and implement new products and technologies, and protect and maintain critical intellectual property assets, (4) cost inflation and availability of raw materials, (5) evolving legal, regulatory, tax and tariff policies and regimes, (6) potential liabilities arising out of the installation and use of ChampionX’s products, (7) continuing consolidation within ChampionX’s customers’ industry, (8) a failure of ChampionX’ s information technology infrastructure or any significant breach of cyber security, (9) risks relating to ChampionX’s international operations and expansion into new geographic markets, including disruptions in the political, regulatory, economic and social conditions of those countries, (10) failure to attract retain and develop key management (11) credit risks, including bankruptcies among ChampionX’s customer base or the loss of significant customers. (12) dependence on joint venture and other local partners, (13) deterioration in future expected profitability or cash flows and its effect on ChampionX’s goodwill, (14) risks relating to improper conduct by any of ChampionX’s employees, agents or business partners, (15) fluctuations in currency markets, (16) the impact of natural disasters and pandemics, (17) changes in industry-specific conditions, including changes in production by OPEC, (18) the level of ChampionX’s indebtedness, (19) ChampionX’s ability to remediate the material weaknesses in internal control over financial reporting, (20) ChampionX’s ability to realize the anticipated cost synergies and growth opportunities from the merger of Apergy Corporation (“Apergy”) and ChampionX Holding Inc. (the “Merger”), (21) challenges in integrating the businesses of legacy Apergy and legacy ChampionX, (22) tax liabilities that could arise as a result of the Merger, (23) ChampionX’s ability to successfully replace the corporate services and financial strength legacy ChampionX received from Ecolab Inc. (“Ecolab”), (24) limitations on ChampionX’s ability to engage in certain transactions and certain activities competitive with Ecolab, and (25) other risk factors detailed from time to time in ChampionX’s reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on ChampionX’s forward-looking statements. Forward-looking statements speak only as of the day they are made and ChampionX undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Investor Contact: Byron Pope
[email protected]
281-602-0094

Media Contact: John Breed
[email protected]
281-403-5751

 

SACRAMENTO, CA, Dec. 14, 2020 (GLOBE NEWSWIRE) — via NewMediaWire – Today BrewBilt Manufacturing Inc. (the “Company”) (OTCPINK: BBRW), announced the appointment of Bennett Buchanan in charge of sales and marketing of the manufacturing of brewery systems and contract-brewing for future private-label customers and BrewBilt’s Brewery brand of craft beers. 

Jef Lewis, CEO, stated, “Ben Buchanan is a 36-year-old overachiever. As the co-founder and brewer for the award-winning Old Bus Tavern brewpub in San Francisco, he has over a decade working in the industry and has honed his skills brewing on a production scale for the Fort Point Beer Company. Ben holds a Bachelor of Science in Civil Engineering and a Masters of Engineering Management from Cornell University.”

Jef Lewis further stated “Our core brew team is implementing an independent public company that will brew its own brand and contract-brew craft beers for our existing customers in the domestic and international craft beer markets in order to drive additional new business our way. In addition to brewing craft beers the brewing company will be diversifying into other types of beverages including CBD-infused and cannabis-infused beverages. BrewBilt Manufacturing Inc. and BrewBilt Beverages Inc. will compliment each other and cross pollinate the development of new revenue. The new company, BrewBilt Beverages Inc. will also offer a selection of white label beers, developed by its core brew team for rebranding by establishments without in-house brewing programs. Many of BrewBilt Beverages’ white label customers, after demonstrating the benefits of offering house beer, have requested that we brew their own beers in-house, leading them back to BrewBilt Manufacturing for the fabrication and installation of a pub-sized brewery system. With 5 years of existing customers combined with recent advertising in major industry publications such as Pizza Today, Food & Beverages, and Beverage Master; Brewbilt Manufacturing has received significant interest in brewpub systems. Even if these establishments decide not to purchase their own brewery, they would still be excellent candidates for BrewBilt Beverages’ white label brews. This circular relationship with customers ensures that BrewBilt always has something valuable to offer to the craft beer industry.”

Watch Video Success Stories:

https://www.brewbilt.com/meet-the-chairman

https://www.youtube.com/watch?reload=9&v=eAtMrDj7PYA&feature=youtu.be

ABOUT BREWBILT: (www.brewbilt.com)

Located in the Sierra Foothills of Northern California, BrewBilt is one of the only California companies that custom designs, hand crafts, and integrates processing, fermentation and distillation processing systems for the craft beer, cannabis and hemp industries using “Best in Class” American made components integrated with stainless steel processing vessels using only American made steel. Founded in 2014, the company began in a backyard shop by Jef Lewis with a vision of creating a profitable company in “Rural America.” BrewBilt has built a solid foundation by having strong relationships with local suppliers of raw materials, equipment and services in California, an aggressive referral network of satisfied customers nationwide, and an Advisory Board consisting of successful business leaders that provide valuable product feedback and business expertise to management. The craft brewing & spirits industries continue to grow worldwide. California is where craft brewing began and now has over 900 operating breweries – being centrally located in this booming market was a large draw for BrewBilt to locate its manufacturing facility in the Sierra foothills. All BrewBilt products are designed and fabricated as “food grade” quality which enables the company to build vessels for food & beverage processing. More important, the company has been building systems that are pharmaceutical grade for clients involved in distillation for the cannabis and hemp industries over the past 36 months, thus making the revenue potential much greater. 

FORWARD-LOOKING STATEMENTS: This document contains forward-looking statements.  Forward-looking statements provide current expectations or forecasts of future events and are not guarantees of future performance, nor should they be relied upon as representing management’s views as of any subsequent date.  The forward-looking statements are based on management’s expectations and are subject to a number of risks and uncertainties.  Although management believes that the expectations reflected in such forward-looking statements are reasonable, actual results may differ materially from those expressed or implied in such statements.  Risks and uncertainties that could cause actual results to differ materially include, without limitation, the Corporation’s ability to effectively execute its business plans; changes in general economic and financial market conditions; changes in interest rates; changes in the competitive environment; continuing consolidation in the financial services industry; new litigation or changes in existing litigation; losses, customer bankruptcy, claims and assessments; changes in banking regulations or other regulatory or legislative requirements affecting the Corporation’s business; and changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other regulatory agencies. Management may elect to update forward-looking statements at some future point; however, it specifically disclaims any obligation to do so.

Contact:
Jef Lewis, Chairman and CEO 
BrewBilt Manufacturing Inc. –  BBRW 
Call or Text: 530-802-5023
[email protected]

BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the appointment of Diego Cadavid, M.D., as Chief Medical Officer. Dr. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.

“We are very pleased to welcome Diego to our team,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. “We believe his strong clinical development expertise, in particular with the advancement of small molecules and biologics for the treatment of rare and immunological diseases, will be invaluable as we continue to advance our ongoing clinical programs, including our Phase 3 trial of mavorixafor in WHIM syndrome and our Phase 1b studies in Waldenström’s macroglobulinemia and severe congenital neutropenia, as well as our preclinical pipeline.”

Dr. Cadavid added, “I am very excited to be joining X4 at this time. I believe the clinical profile demonstrated by mavorixafor to date to be compelling and that this promising small molecule drug candidate has great potential to treat a range of rare genetic immune diseases and cancers. I look forward to leveraging my clinical and scientific expertise to support the continued advancement of mavorixafor through the clinic, while progressing our preclinical programs into the clinic as well.”

Dr. Cadavid brings more than 22 years of experience in drug development and academic research to X4, having led multiple programs through all phases of clinical development, including small molecules and biologics for the treatment of rare and immunological diseases. Most recently, Dr. Cadavid served as Senior Vice President and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases, including sickle cell disease and beta-thalassemia as well as muscular dystrophies. Prior to Fulcrum, Dr. Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group. While at Biogen, he also worked as a consultant at the center for immunology and inflammatory diseases at Massachusetts General Hospital (MGH). Dr. Cadavid holds an M.D. in medicine and surgery from the Pontificia Universidad Javeriana in Bogotá, Colombia and is board-certified and a U.S. licensed clinical neurologist. He completed post-doctoral training in microbiology and immunology at the University of Texas Health Science Center in San Antonio, Texas (UTHSCSA) and a clinical neurology residency at Georgetown University, and completed a fellowship in neuropathology at Armed Forces Institute of Pathology. Dr. Cadavid has published more than 100 peer review publications, review papers, and book chapters.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Cambridge, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit www.x4pharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” or other similar terms or expressions that concern X4’s expectations, strategy, plans or intentions. Forward-looking statements include, without limitation, statements regarding the clinical development of mavorixafor in WHIM, Waldenström macroglobulinemia, SCN and other indications. Any forward-looking statements in this press release are based on management’s current expectations and beliefs. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in X4’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 5, 2020, and in other filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.

Investor
Contact:

Dan Ferry, 617-430-7576
LifeSci Advisors  
[email protected]

M
edia
Contact
: 

Monica Rouco Molina, 929-469-3850 
LifeSci Communications 
[email protected]

MENLO PARK, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that three of the United Kingdom’s leading core laboratories have increased their investment in the company’s Single Molecule, Real-Time (SMRT^®) Sequencing technology. Edinburgh Genomics, Oxford Genomics Centre, and University of Liverpool Centre for Genomic Research have each added Sequel^® II or Sequel IIe Systems to expand the delivery of highly accurate long-read sequencing services to researchers worldwide.

“PacBio supports sequencing labs around the world and we are pleased to expand our collaboration with these important partners in the United Kingdom who share our commitment to providing scientists with the most advanced research technologies,” said Chris Seipert, Vice President of Sales and Support at PacBio. “PacBio HiFi sequencing is enabling scientists to unlock discoveries across a number of important research applications including variant detection and de novo assembly, among others. We look forward to working with our worldwide collaborators to make HiFi sequencing available to anyone seeking industry-leading accuracy and completeness in one easy-to-use technology.”

“The Oxford Genomics Centre, the Core Facility of the Wellcome Centre for Human Genetics, is excited to invest in the PacBio Sequel IIe, introducing their highly-accurate long-read sequencing to Oxford and beyond,” said David Buck, PhD, Head of High-Throughput Genomics at the Oxford Genomics Centre. “This advance will drive new developments in analyses from whole viral sequences to complete assemblies of complex structural regions of the human genome and their epigenetic footprints.”

The PacBio Sequel II and Sequel IIe Systems provide scientists with access to high throughput, cost-effective, highly accurate long-read sequencing. The recently launched Sequel IIe System features hardware and software improvements that enable users to work directly with HiFi reads, the most valuable and informative sequencing data currently available. HiFi reads combine the accuracy of Sanger sequencing (>99.9%) with long reads (up to 25 kb). Together, the length and accuracy of HiFi reads make them ideal for de novo genome assembly, detection of variants from single nucleotide changes to large structural variants, and other genomic or transcriptomic investigations.

“In addition to highly accurate long-reads, HiFi sequencing offers our research customers many important advantages including easy library preparation, low coverage requirements, small file sizes, and fast assembly,” said Javier Santoyo-Lopez, PhD, Service Manager at Edinburgh Genomics, School of Biological Sciences, University of Edinburgh.

Steve Paterson, PhD, Professor of Genetics and Director of the Centre for Genomic Research & NERC Environmental Omics Facility, University of Liverpool commented: “We are excited to have two PacBio Sequel II Systems that we can offer to UK researchers. They will give us the power to look at the richness of genomes across species and to help develop new treatments against microbial infections.”

For more information about the PacBio Certified Service Provider Program, please visit www.pacb.com/CSP.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB), is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to market leadership, uses, accuracy, quality or performance of, or benefits of using, our products or technologies, including SMRT sequencing technology, the expected benefits, suitability or utility of our methods, products or technologies for particular applications or projects, the ability of the Company to be successful in reaching its technological and commercial potential, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

Contacts

Investors: Trevin Rard 650.521.8450
[email protected]

Media: Colin Sanford 203.918.4347
[email protected]

GEORGE TOWN, Grand Cayman, Dec. 14, 2020 (GLOBE NEWSWIRE) — O₂Micro^® International Limited (NASDAQ Global Select Market: OIIM), a global leader in the design, development and marketing of high-performance integrated circuits and solutions, today announced the grant of a patent for a system and method for controlling battery current.

O₂Micro was issued 25 claims under US patent US 10,348,101 B2 for the invention of a system and method for controlling battery current.

This patent applies to a battery system comprised of multiple battery packs, voltage sense circuitry, control circuitry, control switch and current regulation circuitry. This system understands the unique attributes of each battery pack and monitors both current and charging voltage in real time to safely charge and balance battery packs, improve performance and preserve longevity of the battery cells in both conventional and harsh environments.

“This invention enables safe and efficient charging, flexible battery pack pre-conditioning, pack balancing and hot-swap capability to many cordless applications,” said Dr. Guoxing Li, VP of Advanced Technology, O₂Micro. “This technology will allow cordless devices ranging from battery powered garden tools, power tools and cordless vacuums to personal transportation, industrial, sustainable energy storage, and medical devices to operate longer and charge more efficiently without adversely affecting battery longevity.   It also supports hot swap and preconditioning capabilities for next generation applications.”

About O₂Micro:

Founded in April 1995, O₂Micro develops and markets innovative power management components for the Computer, Consumer, Industrial and Automotive markets. Products include Backlighting and Battery Management.

O₂Micro, the O₂Micro logo, and combinations thereof are registered trademarks of O₂Micro. All other trademarks or registered trademarks are the property of their respective owners.

Contact Information: 
Daniel Meyberg
O2Micro Investor Relations
[email protected]

Joe Hassett
Gregory Communications
[email protected]